Literature DB >> 15756540

Vascular damage induced by type 2 diabetes mellitus as a risk factor for benign prostatic hyperplasia.

A P Berger1, M Deibl, E J Halpern, M Lechleitner, J Bektic, W Horninger, G Fritsche, H Steiner, A Pelzer, G Bartsch, F Frauscher.   

Abstract

AIMS/HYPOTHESIS: The aim of this study was to evaluate the relationship between benign prostatic hyperplasia (BPH) and arteriosclerosis shown in a model of type 2 diabetes in a trans-sectional population study using contrast-enhanced colour Doppler ultrasound for exact assessment of prostatic blood flow.
METHODS: Contrast-enhanced transrectal colour Doppler ultrasound was performed using a microbubble-based ultrasound enhancer SonoVue for evaluating prostate vascularity (transitional zone [TZ] and peripheral zone [PZ]) in diabetic BPH patients, non-diabetic BPH patients and healthy subjects. Computer-assisted quantification of colour pixel intensity (CPI) was used to objectively evaluate the prostate vascularity. Resistive index measurements were obtained in the TZ and the PZ. Findings were compared between these three groups.
RESULTS: TZ-CPI was significantly lower in diabetic patients than in non-diabetic BPH men (p=0.001), whereas the CPI of the PZ showed no difference between these two groups (p=0.978). TZ-CPI of patients with diabetic and non-diabetic BPH were significantly lower than in controls (p<0.001), but no difference was found between diabetic and healthy patients in the PZ (p=0.022) and borderline significance was seen when comparing patients of the BPH group with the control patients (p=0.019). Resistive index values of the TZ in diabetic patients showed significantly higher values (p<0.001) than the BPH and control groups. CONCLUSIONS/
INTERPRETATION: The significantly lower CPI and higher resistive index values of the TZ in diabetic patients compared with patients with non-diabetic BPH and healthy subjects indicate considerable vascular damage in the TZ of these patients. Diabetic vascular damage may cause hypoxia and may contribute to the pathogenesis of BPH.

Entities:  

Mesh:

Year:  2005        PMID: 15756540     DOI: 10.1007/s00125-005-1678-6

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  35 in total

Review 1.  Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment.

Authors:  W H Turner; A F Brading
Journal:  Pharmacol Ther       Date:  1997-08       Impact factor: 12.310

2.  Vascularity index as a novel parameter for the in vivo assessment of angiogenesis in patients with cervical carcinoma.

Authors:  W F Cheng; C N Lee; J S Chu; C A Chen; T M Chen; W Y Shau; C Y Hsieh; F J Hsieh
Journal:  Cancer       Date:  1999-02-01       Impact factor: 6.860

3.  Comparison of Laser-Doppler-Flux and tcPO2 in healthy probands and patients with arterial ischemia.

Authors:  L Caspary; A Creutzig; K Alexander
Journal:  Adv Exp Med Biol       Date:  1987       Impact factor: 2.622

4.  Effect of diabetes on lower urinary tract symptoms in patients with benign prostatic hyperplasia.

Authors:  M C Michel; L Mehlburger; H Schumacher; H U Bressel; M Goepel
Journal:  J Urol       Date:  2000-06       Impact factor: 7.450

5.  Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia.

Authors:  J Hammarsten; B Högstedt
Journal:  Eur Urol       Date:  2001-02       Impact factor: 20.096

6.  Detrusor resistive index evaluated by Doppler ultrasonography as a potential indicator of bladder outlet obstruction.

Authors:  A Belenky; Y Abarbanel; M Cohen; O Yossepowitch; P M Livne; G N Bachar
Journal:  Urology       Date:  2003-10       Impact factor: 2.649

7.  Role of Doppler ultrasound and resistive index in benign prostatic hypertrophy.

Authors:  Nobuo Tsuru; Yutaka Kurita; Hiroaki Masuda; Kazuo Suzuki; Kimio Fujita
Journal:  Int J Urol       Date:  2002-08       Impact factor: 3.369

8.  Association between coronary heart disease and cancers of the breast, prostate, and colon.

Authors:  A I Neugut; D J Rosenberg; H Ahsan; J S Jacobson; N Wahid; M Hagan; M I Rahman; Z R Khan; L Chen; A Pablos-Mendez; S Shea
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-10       Impact factor: 4.254

9.  Breast carcinoma: measurement of tumor response to primary medical therapy with color Doppler flow imaging.

Authors:  R P Kedar; D O Cosgrove; I E Smith; J L Mansi; J C Bamber
Journal:  Radiology       Date:  1994-03       Impact factor: 11.105

10.  Relationship between fasting plasma glucose, atherosclerosis risk factors and carotid intima media thickness in non-diabetic individuals.

Authors:  T Temelkova-Kurktschiev; C Koehler; F Schaper; E Henkel; A Hahnefeld; K Fuecker; G Siegert; M Hanefeld
Journal:  Diabetologia       Date:  1998-06       Impact factor: 10.122

View more
  10 in total

Review 1.  Benign prostatic hyperplasia: dietary and metabolic risk factors.

Authors:  H Nandeesha
Journal:  Int Urol Nephrol       Date:  2008-02-02       Impact factor: 2.370

2.  Prostate angiogenesis in development and inflammation.

Authors:  Letitia Wong; Jerry Gipp; Jason Carr; Christopher J Loftus; Molly Benck; Sanghee Lee; Vatsal Mehta; Chad M Vezina; Wade Bushman
Journal:  Prostate       Date:  2013-11-30       Impact factor: 4.104

Review 3.  Diabetes and benign prostatic hyperplasia: emerging clinical connections.

Authors:  Aruna V Sarma; J Kellogg Parsons
Journal:  Curr Urol Rep       Date:  2009-07       Impact factor: 3.092

Review 4.  A comprehensive review of urologic complications in patients with diabetes.

Authors:  Fernando Arrellano-Valdez; Marta Urrutia-Osorio; Carlos Arroyo; Elena Soto-Vega
Journal:  Springerplus       Date:  2014-09-23

5.  Studying the effect of type 2 diabetes mellitus on prostate-related parameters: A prospective single institutional study.

Authors:  Ahmed Elabbady; Mohamed M Hashad; Ahmed F Kotb; Ali E Ghanem
Journal:  Prostate Int       Date:  2016-08-03

6.  Prostatic vascular damage induced by cigarette smoking as a risk factor for recovery after holmium laser enucleation of the prostate (HoLEP).

Authors:  Huan Xu; Chong Liu; Meng Gu; Yanbo Chen; Zhikang Cai; Qi Chen; Zhong Wang
Journal:  Oncotarget       Date:  2017-02-21

7.  Fasting blood glucose level and hypertension risk in aging benign prostatic hyperplasia patients.

Authors:  Hao Zi; Xue-Jun Wang; Ming-Juan Zhao; Qiao Huang; Xing-Huan Wang; Xian-Tao Zeng
Journal:  Aging (Albany NY)       Date:  2019-07-03       Impact factor: 5.682

8.  Impact of Diabetes Mellitus on Lower Urinary Tract Symptoms in Benign Prostatic Hyperplasia Patients: A Meta-Analysis.

Authors:  Caihong Xin; Huaying Fan; Jing Xie; Jingcheng Hu; Xin Sun; Qiuchen Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-01       Impact factor: 5.555

9.  The impact of diabetes type 2 in the pathogenesis of benign prostatic hyperplasia: a review.

Authors:  K Stamatiou; M Lardas; E Kostakos; V Koutsonasios; E Michail
Journal:  Adv Urol       Date:  2009-11-09

10.  Diabetes mellitus and prostate cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial.

Authors:  Michael F Leitzmann; Jiyoung Ahn; Demetrius Albanes; Ann W Hsing; Arthur Schatzkin; Shih-Chen Chang; Wen-Yi Huang; Jocelyn M Weiss; Kim N Danforth; Robert L Grubb; Gerald L Andriole
Journal:  Cancer Causes Control       Date:  2008-07-10       Impact factor: 2.506

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.